Western blot analysis of Phospho-REDD1 pThr23+pThr25 in Jurkat lysate using a Phospho-REDD1 pThr23+pThr25 polyclonal antibody (Product # PA5-35407). Results show a band at ~34kDa. Immunolabeling is blocked by the phospho-peptide used as antigen (lane 2) but not by the corresponding dephospho-peptide (not shown).
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr23/25 of human DDIT4 conjugated to KLH|
|Storage buffer||0.1M HEPES, pH 7.5, with 50% glycerol, 0.1mg/ml BSA, 0.15M NaCl|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with chimpanzee based on 100% sequence homology.
This antibody contains enough material to conduct 10 mini-Western blots.
RTP801 was initially identified as a gene induced by DNA damage, and later found to also be regulated by other cellular stresses such as hypoxia and glucocorticoid treatment. Recently, RTP801 has been shown to act as a mediator of tuberous sclerosis complex (TSC)-dependent regulation of the mammalian Target of Rapamycin (mTOR), an evolutionarily conserved serine/threonine kinase that regulates cell growth and cell cycle. In response to energy stress, RTP801 inhibits mTOR function, resulting in dephosphorylation of downstream targets such as ribosomal protein S6 kinase 1 and 4EBP1 and decreasing cell growth. Disregulation of RTP801 may thus contribute to human tumorigenesis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.